Nearly a year after dropping its lead program and sinking its stock, Unity Biotechnology appears to be coming back on track with positive data in its phase 1 study in patients with advanced vascular ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate was ...